Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study.
Laure GossecStefan SiebertPaul BergmansKurt de VlamElisa GremeseBeatriz Joven-IbáñezTatiana V KorotaevaFrederic LavieWim NoëlMichael T NurmohamedPetros P SfikakisMohamed SharafElke TheanderJosef S SmolenPublished in: Annals of the rheumatic diseases (2022)
At 3 years, there was generally comparable persistence after ustekinumab or TNFi treatment, but AE rates were lower with ustekinumab.